Which option looks more grounded today

For a patient weighing today’s evidence rather than marketing claims, BMAC currently has the firmer clinical footing in knee osteoarthritis. That is still a cautious verdict, not a blank cheque. A 2023 meta-analysis of 27 Level I studies found that BMAC and PRP produced better post-injection outcomes than hyaluronic acid, but BMAC was not significantly better than PRP. More recent review literature in 2025 also suggests short- to mid-term pain and function gains, while stressing that results are inconsistent and long-term benefit is not yet settled. In a 2023 prospective trial of 102 patients, those with Kellgren–Lawrence grade 2 disease did better than patients with grades 3 and 4, which fits the broader pattern that earlier OA may respond more favourably.

Exosome injections sit in a different category at present: promising, but still research-adjacent. The human signal is early, including a 2025 randomised, double-blind, ascending-dose study reporting no adverse consequences and some improvement in clinical scores and MRI findings. Even so, the FDA states there are no approved exosome products for treating disease, and unapproved regenerative products should be used under FDA oversight in clinical trials. In practical terms, that makes BMAC the more usable evidence-based option today, while exosomes require a noticeably higher bar for scrutiny.

What the BMAC evidence actually shows

Kept to the trial evidence alone, the main BMAC story in knee osteoarthritis is about pain relief and function, not proven cartilage repair. The strongest anchor remains the 2023 meta-analysis of 27 Level I studies: the clearest advantage was over hyaluronic acid, while the evidence did not show a significant post-injection difference between BMAC and PRP. In other words, BMAC may improve symptoms, but the best-supported claim is not that it rebuilds a worn knee.

The practical signal becomes clearer when outcomes are broken down. In a 2023 prospective trial of 102 patients, intra-articular BMAC was associated with improvement in KOOS, Oxford Knee Score and VAS pain at 1 and 6 months. That same study suggests the treatment fits earlier osteoarthritis better than more advanced disease, because patients with Kellgren–Lawrence grade 2 did better than those with grades 3 and 4. That does not make BMAC ineffective in later OA, but it does make the evidence less convincing there.

What is still missing is just as important. A 2025 review describes a literature base with different harvest sites, processing methods, cell yields and injection protocols, so study-to-study comparisons remain messy and long-term conclusions are still limited. Taken together, BMAC has a credible short- to mid-term symptom signal in knee OA, but cleaner head-to-head trials, standardised protocols and stronger long-term data are still needed before any broader claim can be made.

How to compare BMAC specialists

Among BMAC providers, the comparison is much narrower than a general clinic checklist: the useful differences sit behind the sales language. A 2025 review found that BMAC studies are difficult to compare because harvest site, processing method, injection protocol and patient selection vary so widely. In practice, that makes protocol transparency more valuable than broad claims about “stem cells” or “regeneration”.

Those protocol details are not trivial. A 2022 study reported that younger patients had higher mononucleated cell yields, and that in older patients an iliac crest harvest produced higher yield and clonogenic capacity than a proximal tibia harvest. A stronger BMAC specialist will therefore explain where marrow is collected, how much is aspirated, how the concentrate is prepared, whether treatment is a single injection or a staged plan, and what rehabilitation follows in the first 6 months.

The consultation itself should also show clear patient-selection logic. In the 2023 prospective trial of 102 knee OA patients, outcomes varied with disease severity, so a credible clinician should say plainly why a knee with a given KL grade, age profile, activity level, alignment problem or co-existing pathology is, or is not, a reasonable BMAC candidate. Useful comparison points include: how the injection is guided, which outcomes are tracked — for example KOOS, Oxford Knee Score or VAS pain — and what the fallback plan is if symptoms do not improve. A balanced service will also place BMAC alongside exercise-based care, weight management, PRP, hyaluronic acid and, where relevant, surgical pathways, rather than presenting one procedure as the answer to every painful knee.

Where exosome injections stand now

Exosomes sit in a different category of uncertainty from better-studied knee injections. The clearest signal in 2025 is regulatory rather than clinical: the FDA states that exosome products intended to treat disease generally require approval, and that there are currently no FDA-approved exosome products. The same agency says unapproved regenerative medicine products should be used under FDA oversight in a clinical trial before approval. That places exosomes closer to a research-adjacent option than to established routine care.

The human knee osteoarthritis data are still thin. A 2025 randomised, double-blind, ascending-dose study of human umbilical cord mesenchymal stem cell exosomes reported no adverse consequences and some improvement in clinical scores and MRI findings. That is encouraging, but it remains an early signal from a limited clinical base, not proof of durable benefit across everyday practice. The wider safety backdrop also matters: the FDA has reported serious harms, including infections, tumour formation and blindness, from unapproved regenerative medicine products.

A large share of the positive exosome literature still comes from preclinical work. In 2025, a meta-analysis pooled 28 rat studies and found cartilage-protective and anti-inflammatory effects, but animal data are not the same as patient benefit. Translation is made harder by product variability: source tissue, isolation method, purity, characterisation and dosing are not standardised across studies or clinics. In UK practice, any service offering exosomes needs to explain the product source, how it is characterised, what governance or research framework applies, what consent covers, and how adverse events are monitored.

What to ask any clinic before you decide

At this stage, the useful divide is not between glossy labels such as “regenerative” and “advanced”, but between a consultation that can answer a short, specific set of questions and one that cannot. Rather than replay the 2023 and 2025 evidence already covered, the practical test is whether the clinic can explain its reasoning in terms that match a real knee, a real product and a real follow-up plan.

• “What published evidence are you relying on for a knee like mine — not just for ‘knee pain’ in general, but for my OA grade, age, symptoms and previous treatment history?”
• “Why am I a candidate now, and what findings would make you advise against this injection?” A sound answer should mention factors such as KL grade, alignment, activity level or other joint pathology, not just a sales phrase.
• “How is the product or concentrate actually prepared?” For BMAC, that means the harvest site, processing method and whether the protocol is a single injection or part of a staged plan.
• “How is the injection delivered, and which outcomes will you track afterwards?” Useful anchors are standard scores such as KOOS, Oxford Knee Score or VAS pain, with a stated review point rather than a vague promise.
• “What level of benefit is realistic, how long might it last, what are the main risks, and what is the fallback plan if it does not help?” The alternatives should include non-injection care and other established pathways, not only another paid procedure.
• For any exosome offer, the key questions are even more specific: “Is this part of a formal study or other regulated framework? What is the source material, how is it manufactured and characterised, and how are adverse events monitored and reported?”

Finding a specialist who fits your situation

In 2025, the useful next step is not another clinic checklist but choosing the right kind of appointment. One person may need the diagnosis clarified, another an injection assessment, another a rehabilitation plan, and another a surgical opinion. A good consultation may still end with advice not to have an injection at all — particularly when knee osteoarthritis is more advanced, or when the proposed treatment sits closer to research than routine practice.

Across the UK, filtering by region, specialty and treatment offered is usually more helpful than assuming the nearest clinic is the best fit. Search MSK lists specialists across the UK who offer knee OA assessment and relevant injection options, with filters by region and specialty.